Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11018452 | 0.81 | TRPA1 (0.58) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL4439739 | 0.81 | GSTP1 (0.52) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL3101177 | 0.81 | GSTP1 (0.52) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL27987589 | 0.81 | DPP4 (0.59) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL930976 | 0.79 | GSTP1 (0.50) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL28849409 | 0.79 | PTGER1 (0.51) | GSTP1HDAC4HDAC2HDAC8SLC6A2 | |
| SCHEMBL30491158 | 0.79 | GSTP1 (0.70) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL28508645 | 0.79 | GSTP1 (0.70) | GSTP1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL7528122 | 0.79 | NPC1 (0.59) | PDK2CCNCCDK8KDM4E | |
| SCHEMBL30985289 | 0.78 | HDAC4 (0.45) | GSTP1HDAC4HDAC2HDAC8ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | GSTP1 3679/4885HDAC4 4521/4885HDAC2 4599/4885 |
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | GSTP1 2075/4885HDAC4 1926/4885HDAC2 1280/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | GSTP1 752/4885HDAC4 1564/4885HDAC2 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.